We reviewed 37 studies reporting long-term outcomes after a status epilepticus (SE) episode in pediatric and adult populations. Study design, length of followup, outcome measures, domains investigated (mortality, SE recurrence, subsequent epilepsy, cognitive outcome, functional outcome, or quality of life), and predictors of long-term outcomes are summarized. Despite heterogeneity in the design of prior studies, overall risk of poor long-term outcome after SE is high in both children and adults. Etiology is the main determinant of outcome, and the effect of age or SE duration is often difficult to distinguish from the underlying cause. The effect of the treatment on long-term outcome after SE is still unknown.
| LITERATURE SEARCH
We performed a search of the medical literature using the following strategy in PubMed: ("status epilepticus") AND ("long-term outcome" OR "long-term mortality" OR "longterm morbidity" OR "quality of life"), gathering 570 articles. Our search was restricted to full-length clinical studies in humans written in the English language until December 1, 2017. We excluded studies focusing on the neonatal period (1-28 days of postnatal age at the beginning of SE) and studies evaluating solely short-term outcome or very specific subgroups of patients. In addition, we added relevant articles from the reference lists of articles from the primary search. We included the results of 37 relevant studies, 16 on children (Table 1 ), 14 on adults and seven on a mixed population of adults and children (Table 2) , reporting longterm outcomes after SE (ie, after hospital discharge or >1 month from SE onset), and reviewed studies for predictors of outcome ( Figure 1 ).
| DEFINITIONS
In 15 pediatric studies, SE was defined as any seizure lasting >30 minutes or recurrent seizures lasting a total of >30 minutes without the subject fully regaining consciousness by most studies, except for one paper that used a 5-minute limit. 6 In 21 studies including adults, definitions were more variable, including 30-minute seizure duration limits, 7-13 and 5-minute clinical seizure duration or more than two seizures without return to baseline between seizures. [14] [15] [16] [17] [18] [19] One study also chose a 10-minute clinical seizure duration cutoff limit. 20 Two studies reported patients with prolonged refractory SE, including patients with SE that persists or recurs over a period of ≥7 days after the initiation of continuous general anesthesia. 21, 22 Super-refractory SE (SRSE) was defined as SE that continues or recurs ≥24 hours after the onset of anesthesic therapy, including those cases that recur on the reduction or withdrawal of anesthesia. 23 Of note, the definition of RSE was also variable, but usually referred to SE that continues after administration of a benzodiazepine and a second antiseizure medication. One study defined RSE as SE lasting >60 minutes. 24 
| APPROACH TO INTENSIVE CARE UNIT TREATMENT OF SE
Treatment of SE mostly follows general treatment guidelines and algorithms. 1, 2 The first line usually consists of benzodiazepines, often followed by intravenous nonbenzodiazepine antiseizure medications (ASMs). If SE continues and becomes refractory, guidelines recommend transfer to the intensive care unit and additional anesthetic treatment, ideally within 30 or 40 minutes after SE onset. 1, 2, 25 The most common drugs at this treatment stage are continuous infusions of midazolam, infusions of pentobarbital/thiopental, or intermittent phenobarbital doses. 1 Main adverse events may include respiratory depression and hypotension, and thus mechanical ventilation and blood pressure management are often needed. 25 Currently, class I evidence supports the use of benzodiazepines as first-line treatments, and a major randomized controlled trial is in progress in an attempt to obtain data supporting choices of secondline treatment (Established Status Epilepticus Treatment Trial). Limited data support third-line treatment choices. 
| LONG-TERM OUTCOMES OF SE

| Subsequent epilepsy
The risk of subsequent epilepsy after SE is high in both children and adults, with highest onset risk during the first year of follow-up. 4 In pediatric patients, this risk ranges from 5% to 36%. 6, [26] [27] [28] [29] In mixed populations of adults and children, subsequent epilepsy after SE may occur in 22%-41%, 14, 30 which is less than in patients with history of RSE, who have a 87.5% risk of subsequent epilepsy.
14 Only one adult study showed that 31% of patients have subsequent epilepsy or worsening of previous epilepsy after SE. 20 The main predictor of subsequent epilepsy is the underlying SE etiology, and nonfebrile-nonidiopathic, 28 remote symptomatic, 29 structural, and acute symptomatic (eg, anoxic brain injury) 30 etiologies are usually associated with higher risk. In comparison, the risk of subsequent epilepsy after a single seizure is 40%-50%. 31, 32 In terms of epilepsy severity after SE, epilepsy becomes refractory in 15%-25% of children after SE, which is not markedly different from the proportion of refractory cases in the general
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The patient who had SE also had a lower probability of epilepsy remission off ASMs (39% vs 65%; risk ratio = 0.50, 95% confidence interval = 0.27-0.95, P = 0.029), 34 suggesting a more refractory epilepsy in these patients. 33, 34 In contrast, a study of 188 children with focal epilepsy found no statistically significant difference in the probability of epilepsy remission off ASM in patients who have SE events (61% in patients with SE vs 66% in patients without SE, P = 0.5). 
| Recurrence of SE
In patients with SE, the occurrence of recurrent SE ranges from 10% to 56% in children 28, 29, 34, 35 and from 13% to 37% in mixed population of adults and children. 8, 9 Predictors of recurrent SE include age < 4 years, 8 female gender, nonresponse to first ASM for SE, 9 and remote symptomatic and progressive etiologies. Cognitive, functional, and QoL sequelae are frequent, especially in RSE and SRSE. 16, 20 Long-term cognitive sequelae occur in 28%-34% of children. 28, 33, 36, 37 In one adult study on long-term cognitive sequelae after SE, no cognitive decline was found after 3 years of follow-up, but this series included only 15 patients. 10 Cognitive outcomes are usually evaluated based on clinical judgment or measured using a wide variety of neuropsychological tests. The underlying etiology is the main factor associated with long-term (Table 1) . Also, seizure burden in uncontrolled epilepsy, rather than SE, is more frequently associated with poor cognitive outcome. 39, 40 The impact of SE on cognitive outcome is debatable. Animal models show that prolonged seizures result in neuronal loss and brain connectivity changes. 41, 42 A clinical study showed that children with SE had worse long-term cognitive outcome than healthy controls, with nonfebrile SE associated with worse cognitive impairments than febrile SE. 37 In contrast, large studies showed no difference in cognitive outcome when comparing children with and without SE, although controls in this study were children with epilepsy. 33, 34 Most adult studies focus on functional rather than cognitive outcomes using standardized scales like the modified Rankin Score and the Glasgow Outcome Scale, with functional deficits seen in 21-61%, 16, 20, 21, 43, 44 and these could be more severe in RSE 20 or SRSE (67%). 16 Functional outcomes in children are mostly based on clinical impression, yielding a wide spectrum of functional impairment after SE from 0% to 79%, 6, 17, 24, [26] [27] [28] [29] 35, 36, 38, 45 and this range may also be related to different definitions and assessment of impairment, and often lack of good baseline information. The evaluation of long-term cognitive outcomes is further complicated by evolution over time in some cases, and in particular outcomes in children are often not static as development progresses. In a pediatric study, impaired performance at discharge persisted at 1 year, 37 whereas in another series deficits disappeared or improved over time. 15, 22, 46 Predictors of poor functional outcome include etiology (nonfebrile SE, acute symptomatic SE, progressive encephalopathy) 17, 26, 28, 36, 37 and SE duration 17, 26, 27, 45 (Table 1) .
T A B L E 2 (Continued)
Authors
| QoL
There is limited literature on QoL after SE. Compared to short seizures, convulsive or electrographic-only SE 45 has a negative impact on the long-term QoL. 5 However, populationbased studies comparing adults with childhood-onset epilepsy with or without SE showed no association with educational attainment, employment status, and income. 33 Patients after RSE may achieve an equivalent QoL as compared to patients after non-RSE. 18 However, patients in seizure remission present better QoL results as compared to patients with SE. 18 Other prospective studies showed only small associations between SE and selected domains of QoL.
34,47
| Mortality
Short-term mortality of SE ranges from 0% to 4% 26, 48, 49 in children and 2%-40% in adults, with higher mortality in RSE. 26, 48, [50] [51] [52] Long-term mortality data after an episode of SE, including in-hospital deaths, is 0%-22% in children 5, 6, 17, [26] [27] [28] [29] [33] [34] [35] 37, 38, 45, 53 and 0%-57% in adults. [10] [11] [12] 17, 19, 20, 43, 54 Although long-term mortality rates are high, the underlying etiology and the period of followup are major determinants of outcome. A population-based study reported 24 deaths among 150 patients with childhood onset epilepsy, but mortality was similar in those with or without prior SE. 34 A prospective study including 206 children identified preexisting neurological comorbidities as a predictor of mortality. 53 Risk factors for mortality in adults include etiology (progressive, remote, or acute symptomatic causes), 8, 12, 13, 24, 55 older age, 11,12 SE duration, 8, 13, 56 and development of subsequent epilepsy. 11 The
Status Epilepticus Severity Score is a valuable tool to assess in-hospital mortality but has not been clearly validated to estimate long-term mortality. [57] [58] [59] The Epidemiology-Based Mortality in Status Epilepticus score considers etiology, age, electroencephalogram, and comorbidities and has been associated with poor long-term outcome in one prospective study. 
| Health care utilization and cost
There are limited data on short-term resource utilization in SE. Studies on mean SE cost estimated up to US$18 834 in the USA and up to €14 946 in Germany per admission, significantly higher than those related to admissions of patients with epilepsy (€1998-€3475). 56, 60, 61 However, these studies reflect the in-hospital treatment, but SE is also associated with indirect costs because of unfavorable outcomes and costs or tentative income loss for those caring for patients with epilepsy. 62 Surprisingly, there is a lack of studies on long-term resource utilization due to SE.
| DIFFERENCES BETWEEN ADULT AND PEDIATRIC POPULATION
Age is one of the main outcome predictors after SE, 53 with the youngest (<1 year) 13, 28, 36, 38 and oldest 11, 12, 20 patients having the poorest long-term outcomes (>65 years 11 or odds/risk ratio = 1.04-1.05/year 12, 20 ). The higher mortality reported in younger children may also reflect the higher proportion of acute symptomatic cases in this age group. [63] [64] [65] Of note, animal models have shown that immature neurons are more resistant to neuronal damage after a prolonged seizure. 66, 67 This may be reflected in the finding that children have fewer cognitive sequelae of SE and lower mortality than adults. 13, 68 However, sequelae in children usually affect a longer expected lifespan than in adults and the elderly. 69 7 | FACTORS AFFECTING OUTCOME
| SE etiology
As in short-term studies, etiology is the main determinant of long-term morbidity and mortality related to SE, probably more than the SE episode itself. 33, 34, 55 A large majority of studies assigned the etiology of SE into broad categories (acute symptomatic, progressive symptomatic, remote symptomatic, and idiopathic/cryptogenic) based on previous work and International League Against Epilepsy recommendations, 70 but the category assignments may in part contain information bias, and various classifications are used.
In adults, etiologies associated with poor outcome include hypoxia, 7, 8, 13 acute symptomatic, 12, 20, 44, 45, 55 and progressive symptomatic causes. 9, 12 In children, many studies have pointed out remote 29, 35, 36 and acute 6, 17, 24, 26, 71 symptomatic causes, progressive encephalopathies, 17, 26, 35, 36 or more extensively "nonfebrile-nonidiopathic SE" 28 as predictors of poor outcome. In contrast, the risks of mortality 53 and neurological deficits are low with febrile SE and cryptogenic/idiopathic SE. [26] [27] [28] 72 However, the specific subcategory of presumed encephalitis or new onset refractory SE may be associated with worse long-term outcome 16, 73, 74 and prolonged duration of SE. 
| Treatment
There is not sufficient evidence for the efficacy of treatment of RSE with anesthetic medications. 2 Notably, some studies suggest that the use of intravenous anesthetic drugs (IVADs) is associated with negative outcomes. 75, 76 Especially pentobarbital has been linked to the development of hypotension requiring prolonged duration of mechanical ventilation and vasopressor therapies, 76 which have in turn been associated with poor longterm outcome. 54 Continuous infusion of thiopental was also associated with more frequent adverse events and worse outcome at 6 months compared to continuous infusions of midazolam. 77 However, it is discussed whether the association with negative outcomes is effectively due to the use of IVADs, or due to confounding by indication, as patients who require continuous infusions are probably more critically ill. 78 A recent prospective two-site cohort study matched 406 patients (139 with IVADs) and found worse outcome in the group receiving IVADs, after adjusting for known outcome predictors. 79 In a review of long-term mortality in relationship to IVADs, the death rate was higher with thiopental/pentobarbital (46%) compared with propofol (36%), midazolam (34%), and ketamine (44%). 80 However, there may be unknown predictors affecting outcome, and therefore additional comparative effectiveness data and randomized controlled trials are needed in this area. Patients with SRSE are more likely to require multiple medication combinations and prolonged hospitalizations and to present severe deconditioning and often systemic complications. Systemic complications of SE can determine long-term morbidity and mortality, including cardiomyopathy, pulmonary edema, and renal failure. 11, 81 It remains unclear how medical treatments affect long-term outcome of SE.
| Short-and long-term effect of acute treatment of SE
Most literature on the treatment of SE considers short-term endpoints like seizure control or in-hospital mortality. Delays in time to treatment are independently associated with worse outcomes in the short term (higher mortality, higher need for continuous infusions, longer convulsive duration, and more frequent hypotension). [1] [2] [3] 33, 82, 83 Families and caregivers play a crucial role, as timely treatment is often possible if families and caregivers administer a rescue medication at home and quickly call emergency services. [84] [85] [86] However, a survey of 100 families of patients with epilepsy showed that 87% had a rescue medication prescription, but only 61% of them reported receiving training on how to use it. 86, 87 Furthermore, a study showed that only 37.5% of patients received prehospital treatment. 85 Improving these factors could impact short-term outcomes. However, the influence of acute treatment of SE on longterm outcomes appears unclear, and the main predictor of long-term outcome appears to be SE etiology. 53 
| LIMITATIONS
Current data need to be interpreted in the setting of often retrospective or unstructured outcome assessment. Additionally, study populations are heterogeneous, different definitions of SE are often applied, and data are acquired in different geographical, socioeconomic, and health care system settings. In addition, follow-up duration and the outcome measures are often variable, reflecting lack of standardized data collection or related guidelines in this field. The current literature does not permit a comparison between results from SE and RSE studies, as they differ in many aspects, including heterogeneity of study populations and study design. Thus far, SE patients are by and large not systematically followed with validated tests repeated over time, or through standardized clinical outcome tools over time. Lastly, we also acknowledge publication bias of specific results, and many publications may suffer from selection and information biases. 
